<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639492</url>
  </required_header>
  <id_info>
    <org_study_id>MBSCLAS01</org_study_id>
    <nct_id>NCT04639492</nct_id>
  </id_info>
  <brief_title>Postbiotic MBS and Metformin Combination in Patients With T2DM</brief_title>
  <official_title>Evaluating the Effect and Safety of Postbiotic MBS and Metformin Combination on Gut Microbiota and Symptom in Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microbio Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Microbio Co Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the effect of MBS treatment in human subjects, and to&#xD;
      validate its impact on intestinal flora and diabetes symptoms on diabetic patients&#xD;
      undertaking metformin. The scientific data collected will be referenced for future product&#xD;
      development.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-treatment changes of intestinal flora</measure>
    <time_frame>4, 8,12 weeks post-treatment</time_frame>
    <description>Post-treatment changes from baseline in microbial composition, abundance, variation of subject's intestinal flora at 4, 8, 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-treatment changes from baseline in fasting plasma glucose at 12 weeks</measure>
    <time_frame>12 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment changes from baseline in HbA1c at 12 weeks</measure>
    <time_frame>12 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment changes from baseline in HOMA-IR at 12 weeks</measure>
    <time_frame>12 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment changes from baseline in blood lipids composition at 12 weeks</measure>
    <time_frame>12 weeks post-treatment</time_frame>
    <description>Changes of triglyceride, high-density lipoprotein (HDL), and low-density lipoprotein (LDL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment changes from baseline in immune factors at 12 weeks</measure>
    <time_frame>12 weeks post-treatment</time_frame>
    <description>Changes of CRP, IL6, TNF-α expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events(TEAE)</measure>
    <time_frame>12 weeks post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type-II Diabetes</condition>
  <arm_group>
    <arm_group_label>MBS oral solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fermented soybean extract-MBS</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MBS oral solution</intervention_name>
    <description>Oral BIDAC, twice a day before breakfast and dinner times</description>
    <arm_group_label>MBS oral solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subject who aged from 20 to 70.&#xD;
&#xD;
          2. BMI in between 18.5 and 35 kg/m2 inclusively.&#xD;
&#xD;
          3. Fasting blood sugar ≥ 126 mg/dL, and confirmed diagnosis of type-II diabetes.&#xD;
&#xD;
          4. 30 days prior to the screening visit (V1), HbA1c is steadily maintained in between&#xD;
             7-10% by medication.&#xD;
&#xD;
          5. Prior to the screening visit (V1), subjects have been regularly taken 500-200 mg/day&#xD;
             for at least 90 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding women or female subjects plan to enter pregnancy during&#xD;
             study period.&#xD;
&#xD;
          2. Subjects who are allergic to soy or products containing it.&#xD;
&#xD;
          3. At investigator's discretion, subjects are unlikely to comply with study procedures&#xD;
             due to a history of alcohol or drug addiction.&#xD;
&#xD;
          4. Subjects on vegetarian diet or other special diets (eg. Ketogenic or gluten-free&#xD;
             diets).&#xD;
&#xD;
          5. Subjects have ongoing participation in another clinical trial that involves the use of&#xD;
             investigational drugs, medical devices, dietary supplements, and/or cosmetics.&#xD;
&#xD;
          6. Subject with impaired renal function confirmed by Serum Total Bilirubin ≥ 1.5 upper&#xD;
             limit of normal [ULN], Aspartate Transaminase/ Alanine Transaminase (AST/ALT) ≥ 2 ULN,&#xD;
             Creatinine ≥ 2 ULN or eGFR &lt;60 mL/min/1.73 m^2.&#xD;
&#xD;
          7. Subjects who have been diagnosed with malignant tumors within five (5) years before&#xD;
             the screening visit (V1) with exception to subjects with topical cancer but show&#xD;
             significant recovery following investigator's assessment, such as basal or squamous&#xD;
             cell skin cancer, superficial bladder cancer, or prostate or cervix or carcinoma in&#xD;
             situ of the breast.&#xD;
&#xD;
          8. 30 days prior to screening visit (V1), subjects have taken antibiotics, synthetic&#xD;
             drugs (Sulfonamides, Fluoroquinolone, etc.), anti-fungal or anti-viral medication but&#xD;
             not limited to topical forms for use in skin application.&#xD;
&#xD;
          9. Within 14 days prior to screening visit (V1), subjects have taken products or&#xD;
             supplements that contain probiotics or prebiotics.&#xD;
&#xD;
         10. Within 14 days prior to screening visit (V1), subjects experience diarrhea caused by&#xD;
             gastrointestinal infection (3 times of watery stool within 24 hours).&#xD;
&#xD;
         11. Within14 days prior to screening visit (V1), subjects have taken steroids,&#xD;
             immunosuppressant, and/or inflammatory medicines.&#xD;
&#xD;
         12. Subjects took or intend to take medications other than metformin that may affect&#xD;
             intestinal flora within 30 days prior to screening visit, during screening period or&#xD;
             whole trial period. Examples of this kind of medication include DPP-4 inhibitors,&#xD;
             GLP-1 receptor agonists, acarbose, hypoglycemic sulfonamides, thiazolidinediones,&#xD;
             SGLT2 inhibitors, and insulin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miicrobio Clinical Project Manager</last_name>
    <phone>+886-2-2703-1298</phone>
    <email>mbclinical@microbio.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Microbio Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>106</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Chao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus (DM)</keyword>
  <keyword>diabetes</keyword>
  <keyword>T2DM</keyword>
  <keyword>MBS</keyword>
  <keyword>microbial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

